GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.
GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...
FiercePharma2d
ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
pharmaphorum1d
ASH: Blenrep ups survival by 42% in multiple myeloma trial
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...
MM&M2d
GSK highlights positive Blenrep data from Phase 3 trial at ASH
GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.
STAT2d
GSK myeloma medicine improves survival in trial, another step in the drug’s revival
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
ENDPOINTS NEWS2d
GSK re­ports Blenrep over­all sur­vival da­ta in mul­ti­ple myelo­ma as it plots mar­ket reen­try
Two years after pulling Blenrep from the market, GSK is positioning for a relaunch. This time, the company says it’s coming ...
GSK announces NMPA of China accepted review of NDA for Blenrep
GSK (GSK) announced that the National Medical Products Administration, NMPA, of China has accepted for review a new drug application, NDA, for ...
STAT2d
Johnson & Johnson seeks first drug approval for treatment of smoldering myeloma
Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...
Hosted on MSN2d
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for ...